Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Aim: the aim of this study is to investigated whether the combination of alflutinib with
cytotoxic chemotherapy might hold additive efficacy, as well as tolerability .
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Henan University of Science and Technology